ESC Premium Access

Prompt initiation of agalsidase alfa therapy is associated with improved cardiovascular outcomes in the Fabry Outcome Survey

Congress Presentation

About the speaker

Professor Ales Linhart

First Faculty of Medicine and General Teaching Hospital, Prague (Czechia)
29 presentations
0 follower

6 more presentations in this session

Comprehensive cardiovascular magnetic resonance assessment of anderson-fabry cardiomyopathy- natural history and assessment of treatment effect

Speaker: Doctor A. Reid (Manchester, GB)


Treatment of Fabry disease with a new oral drug: Initial real-world single-center experience

Speaker: Mr J. Muentze (Wuerzburg, DE)


Efficacy of enzyme replacement therapy in Fabry disease with advanced organ involvement

Speaker: Doctor P. Nordbeck (Wuerzburg, DE)


Long-term benefit of enzyme replacement therapy on cardiac manifestation in Japanese Fabry disease

Speaker: Doctor I. Anan (Tokyo, JP)


Role of serum biomarkers for monitoring disease progression in the cardio-specific alpha-galactosidase A genotype N215S

Speaker: Mr D. Oder (Würzburg, DE)


Access the full session

Cardiomyopathy in Fabry disease

Speakers: Professor A. Linhart, Doctor A. Reid, Mr J. Muentze, Doctor P. Nordbeck, Doctor I. Anan...

About the event


ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb